Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Stem Cell Research & TherapeuticsOpen Access

From missed mutations to liquid clues: a new era of EGFR diagnostics in NSCLC

View Full Paper
Ask AI
Bookmark
Share

Authors

TBTawil BillDNDrew Norma

Discussion

Loading...

Member takes

Overview

Review highlights EGFR-targeted therapies and liquid biopsy's role in enhancing mutation detection and precision oncology.

Key Points

  • Liquid biopsy improves mutation detection in non-small cell lung cancer, enhancing clinical decision-making.
  • Current techniques like PCR, NGS, and ddPCR are assessed for efficacy, revealing limitations in traditional methods.
  • The review explores CRISPR-based diagnostics and nanotechnology's potential to revolutionize EGFR detection.
  • Integrating high-sensitivity approaches may optimize patient outcomes in EGFR-driven malignancies.

Cite This Study

Bill et al. (2025) studied this question.

synapsesocial.com/papers/68c189e09b7b07f3a0613bd7https://doi.org/10.15406/jsrt.2025.10.00193
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Artificial intelligence-driven methods and nanoparticle-based biosensors for rapid and sensitive detection of EGFR mutations in non-small cell lung cancer2026
  2. 2Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management2025 · 22 citations
  3. 3EGFR Dysregulation in Cancer: From Molecular Mechanisms andKey Mutations to Evolving TKI Strategies and Resistance Mitigation2026
  4. 4Prevalence and Clinical Implications of Somatic and Germline EGFR Mutations in Patients with Non-Small-Cell Lung Cancer2026
  5. 5Recent advances in EGFR-targeted therapies for non-small cell lung cancer2026